Planegg-Martinsried, Germany, 17 October 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma CTCL, today published its Q3 2024 report, presenting all material developments up to 30 September 2024, as well as the Company’s current outlook. The full report is available for […]
Swissmedic has granted Orphan Drug Status for resminostat for treatment of cutaneous T-cell lymphoma (CTCL) ODS benefits include reduced fees in Switzerland Planegg-Martinsried, Germany, 16 July 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage CTCL, received notification from the Swiss Agency for Therapeutic Products […]
Planegg-Martinsried, Germany, 20 June 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today publishes a summary of key highlights from its Annual General Meeting held earlier today in Martinsried, Germany. Read more…
Planegg-Martinsried, Germany, 18 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today published its Q1 2024 report, presenting all material developments up to 31 March 2024, as well as the Company’s current outlook. The full report is available for […]
Removes the requirement to conduct paediatric clinical studies when the development of the medicine is not needed or is not appropriate for children This supports resminostat’s Marketing Authorisation Application in the UK Planegg-Martinsried, Germany, 15 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with […]
